Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan
- 12 February 2013
- journal article
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 16 (5), 667-677
- https://doi.org/10.3111/13696998.2013.778270
Abstract
Objective: To assess healthcare resource utilization and costs in a cohort of US managed care patients with systemic lupus erythematosus (SLE). Methods: Claims data from a large managed care plan were used to identify patients of 18–64 years old with SLE-related claims from 2004–2005. Algorithms were developed to retrospectively categorize patients by disease severity and identify flare episodes by flare severity. Descriptive and multivariate analyses were performed to estimate healthcare resource utilization and costs over a 2-year period for the cohort overall and by disease and flare severity. Results: Among the 2990 patients in the study cohort, disease severity was mild in 789 (26.4%), moderate in 1558 (52.1%), and severe in 643 (21.5%). During the 2-year follow-up period, SLE patients utilized the following categories of care: office visit (99.7%), laboratory service (99.5%), outpatient hospital visit (76.0%), emergency room visit (45.6%), and inpatient hospital stay (26.4%). Mean total unadjusted healthcare cost per patient was $30,010 over the 2-year follow-up period, with medical and pharmacy costs comprising 76.5% and 23.5% of total expenditures, respectively. Additionally, 95.7% of patients had one or more flares, with a mean (SD) of 6.7 (3.6) flares during the 2-year follow-up period. The average unadjusted cost per mild, moderate, and severe flare, respectively, was $909, $1539, and $17,059, most of which was for medical cost rather than pharmacy cost. The frequency and cost of flares increased with disease severity. Limitations: The disease severity and flare severity algorithms were based upon managed care claims data; the algorithm was not verified clinically and may not be generalizable to other health plans. Conclusions: SLE is associated with high levels of healthcare utilization and costs in a managed care health plan. Inpatient hospital stays were the primary medical cost drivers, followed by physician office visits and outpatient hospital visits.Keywords
This publication has 38 references indexed in Scilit:
- Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decadeAnnals Of The Rheumatic Diseases, 2010
- The Impact of Systemic Lupus Erythematosus on EmploymentThe Journal of Rheumatology, 2009
- Understanding the Epidemiology and Progression of Systemic Lupus ErythematosusSeminars in Arthritis and Rheumatism, 2009
- Direct and Indirect Costs to Employers of Patients With Systemic Lupus Erythematosus With and Without NephritisJournal of Occupational and Environmental Medicine, 2009
- Employment and disability issues in systemic lupus erythematosus: A reviewArthritis Care & Research, 2008
- Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: Mortality risk and quality of life early in the course of diseaseArthritis Care & Research, 2008
- Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: Estimates obtained using hospitalization dataArthritis & Rheumatism, 2007
- Systemic lupus erythematosusThe Lancet, 2007
- Investigation of Systemic Lupus Erythematosus in Nogales, ArizonaAmerican Journal of Epidemiology, 2001
- Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992Arthritis & Rheumatism, 1999